{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:26:16Z","timestamp":1779391576145,"version":"3.53.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Innovation Team about the Study of Pathogenesis"},{"name":"Anti-tumor Mechanism of Chinese-Tibetan Medicine"},{"name":"Qinghai province Medical Gene Detection Technology Platform"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.critrevonc.2020.103114","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T03:04:55Z","timestamp":1601607895000},"page":"103114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis"],"prefix":"10.1016","volume":"156","author":[{"given":"Fuxing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengfeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoshuang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raees","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuda","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.103114_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1371\/journal.pmed.1000281","article-title":"Prognostic significance of subtype classification for short-and long-term survival in breast Cancer: survival time holds the key","volume":"7","author":"Ambs","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0010","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast Cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103114_bib0015","first-page":"139","article-title":"Management of cardiovascular disease in women with breast Cancer","volume":"02","author":"Barish","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103114_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx134","article-title":"OPtimal duration of extended adjuvant endocrine therapy for early breast Cancer; results of the IDEAL trial (BOOG 2006-05)","volume":"110","author":"Blok","year":"2018","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0025","series-title":"Adjuvant Endocrine Therapy for Women with Hormone Receptor\u2013Positive Breast Cancer","author":"Burstein","year":"2020"},{"key":"10.1016\/j.critrevonc.2020.103114_bib0030","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor\u2013positive breast Cancer: asco clinical practice guideline focused update","volume":"37","author":"Burstein","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0035","article-title":"Hazard of recurrence among women after primary breast Cancer treatment-a 10-Year follow-up using data from SEER-Medicare","author":"Cheng","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"October(5)","key":"10.1016\/j.critrevonc.2020.103114_bib0040","article-title":"Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials","volume":"7","author":"Clement","year":"2018","journal-title":"Gland Surg."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0045","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Breast Cancer Version 3.2019-September 6, 2019. NCCN Guidelines for Patients\u00ae available at www.nccn.org\/patients."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0050","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0055","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"January 15 (2)","key":"10.1016\/j.critrevonc.2020.103114_bib0060","article-title":"Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women","volume":"19","author":"Demissie","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30419-9","article-title":"Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial","author":"Derks","year":"2017","journal-title":"Lancet Oncol."},{"issue":"January 11(8785)","key":"10.1016\/j.critrevonc.2020.103114_bib0070","article-title":"Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 Women","volume":"339","author":"EARLY BREAST CANCER TRIALISTS\u2019 COLLABORATIVE GROUP","year":"1992","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103114_bib0075","article-title":"Tamoxifen for early breast cancer","author":"Early Breast Cancer Trialists\u2019Collaborative Group","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0080","first-page":"69","article-title":"Reversal of tamoxifen induced endometrial modififi cations by switching to letrozole: a prospective transvaginal ultrasound (TVUS) study in early breast cancer [abstract 276]","volume":"22","author":"Garrone","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0085","series-title":"Abstract GS3-01: a Prospective Randomized Multi-center phase-III Trial of Additional 2 Versus Additional 5 Years of Anastrozole After Initial 5 Years of Adjuvant Endocrine Therapy-results from 3,484 Postmenopausal Women in the ABCSG-16 Trial","author":"Gnant","year":"2018"},{"issue":"1","key":"10.1016\/j.critrevonc.2020.103114_bib0090","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx141","article-title":"Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast Cancer: a systematic review and meta-analysis","volume":"110","author":"Goldvaser","year":"2018","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-89-2-157","article-title":"Menopause and coronary heart disease. The Framingham study","volume":"89","author":"Gordon","year":"1978","journal-title":"Ann. Intern. Med."},{"issue":"17","key":"10.1016\/j.critrevonc.2020.103114_bib0100","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast Cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103114_bib0105","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1757","article-title":"Effects of steroidal and nonsteroidal aromatase inhibitors on markers of boneturnover in healthy postmenopausal women","volume":"9","author":"Goss","year":"2007","journal-title":"Breast Cancer Res."},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2020.103114_bib0110","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1470-2045(14)70035-X","article-title":"Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B) a companion analysis of a randomised controlled trial","volume":"15","author":"Goss","year":"2014","journal-title":"Lancet Oncol."},{"issue":"July 21 (3)","key":"10.1016\/j.critrevonc.2020.103114_bib0115","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"August 05 (3)","key":"10.1016\/j.critrevonc.2020.103114_bib0120","article-title":"Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer","volume":"99","author":"G\u00fcth","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103114_bib0125","article-title":"Cardiovascular disease after aromatase inhibitor use","author":"Haque","year":"2020","journal-title":"JAMA Oncol."},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2020.103114_bib0130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer","volume":"126","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2020.103114_bib0135","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy areassociated with increased mortality in women with breast cancer","volume":"126","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0140","first-page":"343","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"18","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2020.103114_bib0145","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jnci\/djm246","article-title":"Extended adjuvant therapy with anastrozole among postmenopausal breast Cancer patients: results from the randomized austrian breast and colorectal Cancer study group trial 6a","volume":"99","author":"Jakesz","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"June 11 (23)","key":"10.1016\/j.critrevonc.2020.103114_bib0150","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10549-011-1754-1","article-title":"Keating. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients","volume":"131","author":"Jennifer","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2020.103114_bib0160","article-title":"Patient centered experiences in breast cancer predicting long-term adherence to tamoxifen use","volume":"45","author":"Kahn","year":"2007","journal-title":"Med. Care"},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2020.103114_bib0165","article-title":"Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study","volume":"42","author":"Kamaraju","year":"2019","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0170","article-title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in post-menopausal women with breast Cancer: a systematic review and meta-analysis of randomized controlled trials","author":"Khosrow-Khavar","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-006-9193-0","article-title":"Adherence to tamoxifen over the five-year course","volume":"99","author":"Lash","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.critrevonc.2020.103114_bib0180","first-page":"18","article-title":"Cardiotoxic effects of anthracycline-based therapy: what is the evidence andwhat are the potential harms?","volume":"08","author":"Levis","year":"2017","journal-title":"Lancet Oncol."},{"issue":"October(10)","key":"10.1016\/j.critrevonc.2020.103114_bib0185","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0190","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4137\/CMO.S8511","article-title":"Treatment-induced bone loss and fractures in Cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab","volume":"6","author":"Lipton","year":"2012","journal-title":"Clin. Med. Insights Oncol."},{"issue":"April 16 (7)","key":"10.1016\/j.critrevonc.2020.103114_bib0195","article-title":"Cohort study of adherence to adjuvant endocrine therapy, breast cancerrecurrence and mortality","volume":"108","author":"Makubate","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"April 20 (12)","key":"10.1016\/j.critrevonc.2020.103114_bib0200","article-title":"Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project b-33 trial","volume":"26","author":"Mamounas","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2020.103114_bib0205","article-title":"Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology\/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"20","author":"Mamounas","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103114_bib0210","article-title":"Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast Cancer cohort","volume":"5","author":"Markkula1","year":"2012","journal-title":"Cancer Prev. Res."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2020.103114_bib0215","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2019.37.15_suppl.504","article-title":"Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: a randomized, phase III study of Gruppo Italiano Mammella (GIM)","volume":"37","author":"Mastro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0220","doi-asserted-by":"crossref","first-page":"k3845","DOI":"10.1136\/bmj.k3845","article-title":"Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review","volume":"363","author":"Matthews","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2020.103114_bib0225","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6604758","article-title":"Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer","volume":"99","author":"McCowan","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2020.103114_bib0230","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000353099","article-title":"Evaluation of factors related to late recurrence \u2013 later than 10 years after the initial treatment-in primary breast Cancer","volume":"85","author":"Nishimura","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2020.103114_bib0235","author":"Ohtani","year":"2019"},{"issue":"February 01 (4)","key":"10.1016\/j.critrevonc.2020.103114_bib0240","article-title":"Predictors of tamoxifen discontinuation among older women with estrogen receptor\u2013Positive breast Cancer","volume":"26","author":"Owusu","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0245","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"For the EBCTCG. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2020.103114_bib0250","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","article-title":"Nonadherence to adjuvant tamoxifen therapy in women with primary breast Cancer","volume":"21","author":"Partridge","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"February01 (4)","key":"10.1016\/j.critrevonc.2020.103114_bib0255","article-title":"Adherence to initial adjuvant anastrozole therapy among women with early-stage breast Cancer","volume":"26","author":"Partridge","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0260","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-019-05464-w","article-title":"Efcacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literaturebased meta-analysis of randomized trials","author":"Qian","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0265","doi-asserted-by":"crossref","DOI":"10.5600\/mmrr.001.04.a04","article-title":"Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D","volume":"1","author":"Riley","year":"2011","journal-title":"Medicare Medicaid Res. Rev."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0270","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-010-0952-6","article-title":"Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer","volume":"125","author":"Sedjo","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"October 02 (19)","key":"10.1016\/j.critrevonc.2020.103114_bib0275","article-title":"Factors predicting late recurrence for estrogen receptor\u2013Positive breast Cancer","volume":"105","author":"Sestak","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0280","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(13)70387-5","article-title":"Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population","volume":"14","author":"Sgroi","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0285","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30600-9","article-title":"Dutch Breast Cancer research Group (BOOG) for the DATA Investigators. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial","author":"Tjan-Heijnen","year":"2017","journal-title":"Lancet Oncol."},{"issue":"August(3)","key":"10.1016\/j.critrevonc.2020.103114_bib0290","article-title":"Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis","volume":"122","author":"van Herk-Sukel","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0295","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ctrv.2006.07.012","article-title":"Safety of adjuvant aromatase inhibitor therapy","volume":"32","author":"Venturini","year":"2006","journal-title":"Cancer Treat. Rev."},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2020.103114_bib0300","article-title":"Adherence to adjuvant hormonal therapy and its relationship to breast cancerrecurrence and survival among low-income women","volume":"36","author":"Weaver","year":"2013","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.103114_bib0305","article-title":"Extended adjuvant therapy with aromatase inhibitors for early breast cancer: a meta-analysis of randomized controlled trials","author":"Xu","year":"2020","journal-title":"Clin. Breast Cancer"},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2020.103114_bib0310","article-title":"Breast cancer therapy-associated cardiovascular disease","volume":"13","author":"Zagar","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2020.103114_bib0315","first-page":"27","article-title":"Observation versus late reintroduction of letrozole as adjuvant endocrinetherapy for hormone receptor-positive breast cancer (ANZ0501 LATER): anopen-label randomised, controlled trial","volume":"05","author":"Zdenkowski","year":"2016","journal-title":"Ann. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282030250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282030250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:34:27Z","timestamp":1760902467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282030250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":63,"alternative-id":["S104084282030250X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103114","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103114"}}